Recital 9, Decision_act (EU) 2025/439

In forcesince 28 Feb 2025

During 2023, the Commission gathered data on a range of other substances that could be included in the watch list. It took into account the different types of relevant information referred to in Article 8b(1) of Directive 2008/105/EC, and consulted experts from Member States and stakeholder groups. Substances for which doubt exists about their toxicity, or for which the sensitivity, reliability or comparability of the available monitoring methods are not adequate, should not be included in the watch list. The sunscreen agent 2-ethylhexyl salicylate, also known as octisalate, the industrial antioxidant substance N-1,3-dimethylbutyl-N’-phenyl-p-phenylenediamine (6PPD) and its degradation product 6PPD-quinone, the insecticide and anthelmintic abamectin, a group of azole antifungal substances (bromuconazole, climbazole, cyazofamid, difenoconazole, epoxiconazole, itraconazole, ketoconazole, mefentrifluconazole, propiconazole, triticonazole), the insecticide etoxazole, the antidepressants fluoxetine and propranolol, and the antibiotics oxytetracycline and tetracycline were identified as suitable candidates. The inclusion of the pharmaceuticals is consistent with the EU Strategic Approach to Pharmaceuticals in the Environment [Communication from the Commission to the European Parliament, the Council and the European Economic and Social Committee, European Union Strategic Approach to Pharmaceuticals in the Environment, COM(2019) 128 final, 11 March 2019.], and the inclusion of the two antibiotics is also consistent with the European One Health Action Plan against Antimicrobial Resistance (AMR) [Communication from the Commission to the Council and the European Parliament A European One Health Action Plan against Antimicrobial Resistance (AMR), COM(2017) 339 final, 29 June 2017.], which supports the use of the watch list to ‘improve knowledge of the occurrence and spread of antimicrobials in the environment’.